Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

AB Science's Stock Plummets Over 25% In One Day: What's Causing The Decline?

Loading stream...

(vianews) - shares of ab science suffer 25.35% drop on cac 40, extinction of recent losses on wednesday, shares of ab science (cac 40: ab.pa) experienced an alarming decline of 25.35% to eur1.62, ending their three-session losing streak and showing bearish signs for trading on exchange. the cac 40 also witnessed this dip of 0.13% at eur7,938.44 following its downward trend from previous session; which indicates current bearish trends within market. last time it closed its shares were at eur2.17, 71.03% off its 52-week high of eur7.49. investors may be concerned about ab science's recent performance and its potential effect on future growth; so staying informed on any news or developments related to them in order to make informed decisions regarding their investments is essential for making sound investment decisions.

about ab science

ab science s.a. is a pharmaceutical company focused on researching, developing and marketing protein kinase inhibitors for human and veterinary medicinal use. their lead compound, masitinib (tyrosine kinase inhibitor), has completed phase iii trials for various conditions such as prostate and pancreatic cancer; amyotrophic lateral sclerosis; multiple sclerosis; alzheimer's; severe asthma; mastocytosis diseases as well as covid-19 treatment; they also developed ab8939 synthetic microtubule destabilizer which may have haematology applications ab science was founded in 2001 with headquarters located in paris france

yearly analysis

according to available information, ab science stock is currently trading at eur1.62 - which is below its 52-week low of eur2.18 and suggests it has already hit bottom this year. investors should remember that past performance does not guarantee future outcomes and should perform their own due diligence prior to making investment decisions.

technical analysis

stock price analysis for ab science (abs)ab science's stock has seen a substantial decrease, falling beneath both its 50-day and 200-day moving averages. last reported volume for this stock is 799,966, representing 491.94% above its average volume of 135,143 and signalling high trading activity in its shares. unfortunately, volatility levels over the past month have fluctuated drastically with its intraday variation average showing negative values. ab science's stock currently shows high amplitude average volatility: 14.17% in the last week, 5.42% in the past month and 4.22% over the past quarter. furthermore, the stochastic oscillator indicates that its stock may currently be overbought (>=80), suggesting it could be due for correction in the near future. as a whole, its trading value and volatility do not offer positive prospects to investors. prior to making any investments decisions, investors should carefully monitor and consider various aspects of ab science's stock performance as well as company fundamentals. as of now, its price is currently declining in a bearish trend with moving averages and volatility showing no positive indications. stock is currently considered overbought and this could result in a price correction in the near term. investors should exercise extreme caution and conduct further research prior to making any investment decisions. about the author:john smith has over 10 years of experience working as a financial news specialist. john has an expert understanding of ap style and financial markets as a whole, including their drivers and trends. his writing style is succinct, precise and insightful - providing readers with valuable information and analysis. disclaimer: john does not currently hold any position in any stocks mentioned and no plans to initiate new positions within 72 hours.

quarter analysis

revenue growth in the twelve trailing months, year-on-year quarterly revenue growth decreased by 28.8% and now stands at $77k.

equity analysis

earnings per share (eps) is a financial metric used to gauge how much profit a company generates per outstanding share of stock, calculated by dividing net income by total outstanding shares. ab science has an estimated trailing twelve months eps loss of eur-0.36; this indicates the company incurred a net loss per outstanding share over the last twelve months. eps is an invaluable indicator for investors as it gives an indication of a company's profitability and ability to generate earnings for shareholders. a positive eps indicates a profitable company while negative numbers suggest one may be struggling financially. investors may compare a company's eps against that of its peers or the overall market to get a clearer idea of its performance and growth potential. it should be remembered, however, that eps alone should not be taken into consideration when making investment decisions as it doesn't take into account other important financial metrics like revenue, debt and cash flow.

more news about ab science (ab.pa).